Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences and Arcus Biosciences are collaborating on a clinical study titled A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. The study aims to assess the antitumor activity and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer, a significant area of unmet medical need.
The study tests several interventions, including etrumadenant, a dual adenosine receptor antagonist, in combination with zimberelimab, an anti-PD-1 monoclonal antibody, and other chemotherapy agents like mFOLFOX-6 and bevacizumab. These combinations are designed to enhance the immune response against cancer cells.
The study follows a randomized, parallel assignment model with single masking for outcome assessors. Its primary purpose is treatment-focused, aiming to evaluate the safety and efficacy of these drug combinations in a clinical setting.
The study began on May 10, 2021, with an estimated completion date in 2025. The latest update was submitted on August 7, 2025, indicating ongoing progress in the study.
The outcome of this study could significantly impact Gilead Sciences and Arcus Biosciences’ stock performance by potentially introducing a new treatment option in the colorectal cancer market. Positive results could enhance investor sentiment and position these companies favorably against competitors in the oncology sector.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.